TY  - JOUR
AU  - Aditya, Ishan
AU  - Kwong, Jethro C. C.
AU  - Krakowsky, Yonah
AU  - Grober, Ethan D.
PY  - 2019
TI  - Non-conventional therapies for Peyronie’s disease: what is the evidence for efficacy?
JF  - Translational Andrology and Urology; Vol 9, Supplement 2 (March 05, 2020): Translational Andrology and Urology (Contemporary Issues and Controversies in Men’s Health)
Y2  - 2019
KW  - 
N2  - Background: In recent years, there has been a surge in non-conventional therapies for Peyronie’s disease (PD). With increasing interest in these novel therapies, we conducted a narrative review to explore the efficacy and safety of these treatments to provide clarity for patients and providers.  Methods: A literature search was conducted to find studies describing non-conventional treatments of PD. These treatments were defined as those within the standard of care, including intralesional therapies and surgical options.  Results: A total of 14 studies were found. Non-conventional therapies included platelet-rich plasma (PRP), hyaluronic acid (HA), combination therapy of PRP and HA, extracorporeal shockwave therapy (ESWT), stem cell therapy (SCT), mycophenolate mofetil (MMF), and H-100. Most studies were limited to animal models and reported modest improvements in angulation and erectile function. Complication rates and cost of each treatment were infrequently reported.  Conclusions: There is limited evidence supporting non-conventional therapies for PD. As such, they are currently not recommended in clinical guidelines.
UR  - https://tau.amegroups.org/article/view/31839